Capstone Therapeutics Corp Stock Other OTC
Equities
US14068E1091
Biotechnology & Medical Research
Sales 2022 | 61.56M 84.12M | Sales 2023 | 48.35M 66.07M | Capitalization | 820K 1.12M |
---|---|---|---|---|---|
Net income 2022 | 2M 2.73M | Net income 2023 | -3M -4.1M | EV / Sales 2022 | 0.56 x |
Net Debt 2022 | 28.78M 39.33M | Net Debt 2023 | 20.28M 27.71M | EV / Sales 2023 | 0.44 x |
P/E ratio 2022 |
-583
x | P/E ratio 2023 |
-0.14
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 87-08-31 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 17-07-13 |
Matthew Lipman
BRD | Director/Board Member | 45 | 17-07-13 |
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |